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Abstract
Cancer stem cells (CSCs) or tumor initiating cells (TICs) make up only a small fraction of total tumor cell population, but
recent evidence suggests that they are responsible for tumor initiation and the maintenance of tumor growth. Whether
CSCs/TICs originate from normal stem cells or result from the dedifferentiation of terminally differentiated cells remains
unknown. Here we provide evidence that sustained expression of the proinflammatory protein tissue transglutaminase
(TG2) confers stem cell like properties in non-transformed and transformed mammary epithelial cells. Sustained expression
of TG2 was associated with increase in CD44
high/CD24
low/- subpopulation, increased ability of cells to form mammospheres,
and acquisition of self-renewal ability. Mammospheres derived from TG2-transfected mammary epithelial cells (MCF10A)
differentiated into complex secondary structures when grown in Matrigel cultures. Cells in these secondary structures
differentiated into Muc1-positive (luminal marker) and integrin a6-positive (basal marker) cells in response to prolactin
treatment. Highly aggressive MDA-231 and drug-resistant MCF-7/RT breast cancer cells, which express high basal levels of
TG2, shared many traits with TG2-transfected MCF10A stem cells but unlike MCF10A-derived stem cells they failed to form
the secondary structures and to differentiate into Muc1-positive luminal cells when grown in Matrigel culture.
Downregulation of TG2 attenuated stem cell properties in both non-transformed and transformed mammary epithelial
cells. Taken together, these results suggested a new function for TG2 and revealed a novel mechanism responsible for
promoting the stem cell characteristics in adult mammary epithelial cells.
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Introduction
Metastatic breast cancer is an aggressive, chemoresistant and
essentiallyincurablediseasewithmediansurvivaldurationofabout2
years after metastasis has been detected [1]. Understanding the
molecular mechanisms involved in cancer metastasis is critical for
developing new strategies for improving patient outcomes. Recent
advances in understanding the biology of tumor progression and
metastasis suggest that cancer stem cells (CSC) or tumor-initiating
cells (TIC) are important players in the progression of primary
tumors to metastaticdisease[2].Published studiessuggest that breast
CSCs/TICs are relatively resistant to both chemotherapy and
radiation therapy [3]. Moreover, due to their self-renewal and
differentiation abilities CSCs/TICs can regenerate various subpop-
ulations of the original tumor and endow tumors with the ability to
survive and sustain growth [4].While variousstudieshaveconfirmed
the existence of CSCs/TICs in humans and animal models with
breast cancer [4,5], it remains to be determined whether these cells
originate from resident tissue stem cells or from acquisition of
oncogenic lesions in which more differentiated epithelial cells have
dedifferentiated into a primitive stem cell like state.
Our previous studies have demonstrated that breast tumors and
tumor cell lines selected for resistance to drugs or isolated from
metastatic sites exhibit increased expression of the pro-inflamma-
tory protein tissue transglutaminase [6–9]. In our quest to
determine the significance of increased TG2 expression in cancer
cells, we found that stable expression of TG2 induces epithelial-to-
mesenchymal transition (EMT) in mammary epithelial cells [10].
The TG2-induced EMT is associated with enrichment of the
CD44
high/CD24
low/- cell population, the antigenic phenotype
considered to have CSC/TIC characteristics in non-transformed
and transformed mammary epithelial cells [11].
Based on these observations and the observation that expression
of EMTin mammary epithelial cells is associated withacquisition of
CSC/TIC characteristics [12], we initiated studies to determine
whether TG2-induced EMTcould promote stem cell like properties
in mammary epithelial cells. Here we present, for the first time,
evidence that TG2 expression promotes phenotypic plasticity and
shifts the dynamic equilibrium from non-stem to stem cells by
increasing the number of cells with stem cell like properties. These
results may suggest novel strategies for targeting CSC/TIC
subpopulations in tumors for improved clinical outcomes.
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TG2 expression confers CD44
high/CD24
low phenotype in
mammary epithelial cells
In our previous report we showed that stable expression of TG2
in mammary epithelial cells could induce the EMT and resulted in
enrichment of CD44
high/CD24
low subpopulation [10], the
antigenic phenotype that is linked with normal and transformed
mammary stem cells [11,13]. To further address the significance of
TG2 in promoting CD44
high/CD24
low phenotype, we downreg-
ulated TG2 expression by small hairpin RNA (shRNA) and
determined CD44/CD24 antigen expression. The MCF10A-TG2
cells with induced and MCF7/RT and MDA-231cells with
constitutive TG2 expression were infected with TG2-shRNA or
control-shRNA-lentiviral construct. Following the selection of
stable clones against puromycin, cells were analyzed for CD44/
CD24 expression. Results shown in Figure 1 demonstrated that
downregulation of exogenous (MCF10A-TG2) or endogenous
(MCF7-RT and MDA-231) TG2 is associated with a considerable
decrease in the number of CD44
high/CD24
low cells. No such
change in control-shRNA transfected cells was evident. These
observations further supported the contention that aberrant
Figure 1. TG2 expression confers CD44
high/CD24
low phenotype in non-transformed and transformed breast epithelial cells. (A)
Immunoblot analysis (left panel) showing the expression of TG2 in vector- (MCF10A-Vec), TG2-lentiviral infected MCF10A cells (MCF10A-TG2) and
MCF10A-TG2 cells infected with either control- (sh-control) or TG2-shRNA (shTG2). FACS analysis (Right panel) of cell-surface markers CD44 and CD24
in the cells described in left panel. (B) Immunoblot analysis (left panel) showing basal expression of TG2 in drug-sensitive (MCF-7) and drug-resistant
(MCF7/RT) breast cancer cells and in MCF7/RT cells after their transfection with control or TG2-shRNA. FACS analysis (right panel) for cell-surface
markers CD44 and CD24 in cells described in left panel. (C) Immunoblot analysis (left panel) showing basal expression of TG2 in highly aggressive
MDA-231 breast cancer cells before and after their transfection with control- or TG2-shRNA. FACS analysis (right panel) for CD44 and CD24 antigen
expression in cells described in left panel.
doi:10.1371/journal.pone.0020701.g001
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increased expression of stem cell antigenic markers.
TG2 expression enhances mammosphere-forming ability
in mammary epithelial cells
Beside CD44
high/CD24
low/- antigenic phenotype, the ability to
withstand anoikis, to proliferate and differentiate in anchorage-
independent manner, and to grow in clonal clusters or mammo-
spheres are some additional characteristics of mammary epithelial
stem cells [14,15]. Implantation of in vitro generated mammo-
spheres into the mammary stromal fat pad is able to reconstitute
the entire mammary ductal tree [16,17]. These observations imply
that in vitro ability of cells to form mammospheres represents their
self-renewal and gland-reconstituting abilities [15,18,19]. There-
fore, we next examined the mammosphere forming ability of TG2
expressing mammary epithelial cells. Results shown in Fig. 2
demonstrated that neoexpression of TG2 in MCF10A cells was
associated with .15-fold increase in mammospheres formation
compared to the control vector-infected MCF10A cells (Fig. 2A
and 2B). Similarly, the mammosphere forming ability of breast
cancer cells with high basal TG2 expression (MCF7/RT and
MDA-231) was significantly higher than the TG2-deficient cells
(MCF-7) (Figure 2A and 2B). Importantly, downregulation of TG2
in these cells significantly compromised their ability to form
memmospheres (Fig. 2C). These data further supported the
significance of TG2 in conferring stem cell like attributes in
mammary epithelial cells.
TG2 expression augments the self-renewal ability
Stem cells have two distinct features – the ability of self-renewal
and differentiation into multiple lineages. To test the self-renewal
capability of TG2 expressing cells, we used an in vitro assay that
relies on assessing the sphere-initiation efficiency of serially
passaged cells cultured as mammospheres. Results shown in
Figure 2. TG2 expression promotes mammosphere-forming ability in breast epithelial cells. (A) Phase-contrast images of
mammospheres formed after 10 days’ culture of indicated cells in the mammosphere medium. (B) Quantification of mammospheres formed by
cells (top panel) and immunoblot analysis for TG2 expression (bottom panel) in cells described in (A). (C) Quantification of mammospheres formed by
MCF10A-TG2, MCF7/RT and MDA-231 cells transfected with either control (sh-contol) or TG2 (sh-TG2) shRNA. The data shown are average number of
mammospheres formed/1000 seeded cells 6 SEM from triplicate values of a representative experiment performed three times with similar results.
doi:10.1371/journal.pone.0020701.g002
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number of secondary mammospheres formed by culture of TG2-
deficient MCF10A-Vec and MCF-7 cells, respectively. However,
in subsequent passages the number of mammospheres formed
remained steady (Fig. 3A and 3C) suggesting the maintenance of
dynamic equilibrium between stem cells and non-stem cell
populations. In contrast, the number of cells with mammosphere
forming ability increased with each passage in TG2-induced
MCF10A (Fig. 3B) and endogenously high TG2 expressing
MCF7-RT (Fig. 3D) and MDA-231 cells (Fig. S1). These results
Figure 3. TG2 expression enhances the self-renewal ability of breast epithelial cells. To test the self-renewal ability, we assessed the
sphere-initiation efficiency of serially passaged cells cultured as mammospheres for up to four generations. Number of mammospheres formed by (A)
MCF10A-Vec, (B) MCF10A-TG2, (C) MCF-7 and (D) MCF-7/RT cells at different passages (M1 to M4). (E) Immunoblot analysis showing the expression of
TG2 in MCF-7/RT cells transfected with either control or TG2 shRNA. Number of mammospheres formed by control- (F) and TG2-shRNA (G)-
transfected MCF-7/RT cells during different passages (M1 to M4). The data shown are average number of mammospheres formed/1000 seeded cells
6 SEM from triplicate values of experiments repeated twice with similar results. Please note 10-fold difference in y-axis scales for cells lacking TG2 (0–
35) and TG2 expressing cells (0–350).
doi:10.1371/journal.pone.0020701.g003
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increased ability of mammary epithelial cells for self-renewal. To
further test this contention, TG2 expressing MCF7-RT cells were
stably transfected with control or TG2-shRNA (Fig. 3E) and
assayed for mammospheres forming efficiency in serially passaged
cultures. Similar to the parental MCF-7/RT cells, control shRNA
transfected (MCF-7/RT sh-Control) cells showed progressive
increase in the number of mammosphere initiating cells with each
passage (Fig. 3F). TG2-shRNA transfected cells (MCF7-RT sh-
TG2) in contrast, showed , 2-fold increase in secondary
mammospheres and the proportion of mammosphere-forming
cells remained unchanged in subsequent passages (Fig. 3G).
Overall, these findings suggested that TG2 expression increased
the cellular plasticity and shifted the dynamic equilibrium from
non-stem cells towards stem cell compartment.
TG2-induced stemness is a dynamic process
It is generally believed that non-transformed mammary
epithelial cells show lineage hierarchy in which CD44
high/
CD24
low cells (Stem cells) irreversibly differentiate into
CD44
high/CD24
high cells (non-Stem cells) [20]. Since TG2
expression resulted in cellular plasticity, next we determined
weather its expression maintains such lineage hierarchy or not.
The CD44
high/CD24
low and CD44
high/CD24
high subpopulations
were purified from TG2 overexpressing MCF10A cells by FACS
sorting (Fig. 4A) and purified subpopulations were allowed to grow
in monolayer cultures. Morphologically the cells in two subpop-
ulations looked identical with mesenchymal appearance (Fig. 4B).
To evaluate their stem cell characteristics, we allowed these cells
(p1) to grow in mammosphere cultures. Results shown in Fig. 4B
demonstrated that CD44
high/CD24
low cells were highly efficient in
forming the mammospheres whereas CD44
high/CD24
highcells
under identical conditions failed to grow into mammospheres
(Fig. 4B and 4D). Moreover, the number of mammospheres
formed by CD44
high/CD24
low MCF10A-TG2 cells were higher
than the unsorted MCF10A-TG2 cells (Fig. 2B). Next we allowed
the sorted cells to grow in monolayer cultures for 15 days (p5).
Once again, the cells in two subpopulations after 15 days of culture
appeared similar with mesenchymal morphology (Fig. 4C).
However, assay of these cells for CD44/CD24 expression revealed
some rather surprising results. More than 80% cells in both the
subpopulations showed CD44
high/CD24
low phenotype (Fig. S2)
and they were able to form the mammospheres (Fig. 4C). The
number of mammosphere formed by CD44
high/CD24
High cells
increased while in CD44
high/CD24
low cells it decreased after
culture in monolayers (Fig. 4D). These results suggested that in
presence of constitutive TG2 expression (Fig. 4E), CD44
high/
CD24
high (non-stem) cells have the ability to de-differentiate into
stem cells and CD44
high/CD24
low (stem cell) cells can differentiate
into non-stem cells (Fig. 4E). Overall these observations support
that constitutive expression TG2 increases the phenotypic
plasticity and that TG2-induced stem cellness is dynamic in
nature.
TG2 expression does not affect the differentiation ability
of mammary stem cells
Another important characteristic of stem cells is their ability to
differentiate into multiple lineages. To test the ability of TG2-
expressing cells to differentiate and form secondary structures [14],
we transferred individual mammospheres into Matrigel culture
containing prolactin. Under these culture conditions the mammo-
spheres derived from ‘empty vector’ or TG2-transfected MCF10A
cells differentiated and formed complex secondary structures
representing mammary gland like organotypic outgrowths
(Fig. 5A). Immunostaining of these secondary structures revealed
the presence of both Muc1 (luminal marker) and CD49f/integrin
a6-positive (basal marker) cells (Fig. 5B) suggesting that TG2
expression doesn’t effect the terminal differentiation of mammary
stem cells in response to prolactin treatment. In contrast to
MCF10A cells the mammosphere derived from breast cancer
MDA-231 cells failed to differentiate into secondary structures,
instead they grew into tumor-like mass with cells invading through
the surrounding Matrigel (Fig. 5A). Moreover, immunostaning of
MDA-231-derived secondary structures showed only faint staining
for CD49f/integrin a6-positive (basal marker) cells and did not
show any Muc1 (luminal marker)-positive cells (Fig 5B). These
results suggested that TG2-induced stemness in non-transformed
mammary epithelial cells maintains their ability to terminally
differentiate whereas in cancer cells, TG2 expression though shifts
the dynamic from non-stem to stem cells but these cells lack the
commitment to terminally differentiate.
Discussion
Consistent with our previous observations that increased
expression of TG2 induces EMT in non-transformed and
malignant mammary epithelial cells [10], here we found that
TG2-induced EMT promotes stem cell traits in these cells. Thus,
TG2 expression was associated with increased CD44
high/CD24
low
antigenic phenotype, increased ability to form mammospheres,
increased self-renewal ability and differentiation into luminal and
basal cell types. The first three features were shard by both the
TG2-induced non-transformed MCF10A cells and transformed
MCF7/RT and MDA231 cells, which express high basal levels of
TG2. However, unlike MCF10-TG2 cells the ability of TG2
expressing MDA-231 cells to differentiate in response to prolactin
treatment was lost.
These findings suggest a novel mechanism underlying the
progression of tumor cells to aggressive and invasive phenotype.
Thus, aberrant expression of TG2 in tumor cells promotes
metastasis by inducing EMT and stemness, which in turn
endorses the ability to cancer cells to migrate and grow at
secondary sites. Indeed, it has been proposed that EMT can
enable cancer cells not only to disseminate but also to acquire the
ability of self-renewal by inducing stem cell state [20].
Interestingly, unlike non-transformed mammary epithelial cells,
TG2 expressing cancer cells were unable to undergo differenti-
ation in response to prolactin treatment. The lack of differenti-
ation by transformed cells may reflect the function of some
oncogenic mutation(s) or some other, yet unknown, defect in
these cells. Creighton et al. [21] recently observed that the
residual breast tumor cells in clinical samples surviving after
conventional treatment are enriched in subpopulations of cells
with both tumor-initiating and mesenchymal features, further
supporting the link between EMT and stem cell phenotype. Our
results also provide the evidence that differentiation of stem cells
to non-stem cells and vice versa is a dynamic process. More
recently, Illopoulos et al. [22] arrived a similar conclusion
supporting that tumor heterogeneity involves a dynamic equilib-
rium between stem and non- stem cell compartments and this
plasticity is regulated by interlukin (IL)-6, the inflammatory
cytokine that is known to induce the expression of TG2 in various
cell types [23,24]. Based on these observations, it is tempting to
speculate that IL-6-induced stemness in mammary epithelial cells
may be related to its ability to upregulte TG2 expression. Indeed,
in a related system we recently showed that the proinflammatory
cytokine TGF-b could induce the EMT by virtue of its ability to
upregulate TG2 expression [10].
TG2-Induced Stem Cellness
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20701Figure 4. TG2 induced stem cellness is dynamic in nature. (A) CD44
high/CD24
high cells and CD44
high/CD24
low cells were separated by FACS. (B)
Phase-contrast images of morphology (left) and mammospheres (right) obtained after seeding the CD44
high/CD24
high (top) and CD44
high/CD24
low
(bottom) cells from (A). Magnification x100; inset, X500 (C) Phase-contrast images of morphology (left) and mammospheres (right) obtained by
seeding CD44
high/CD24
high (top) and CD44
high/CD24
low (bottom) cells at the 5
th passage (p5). (D) Quantification of mammospheres formed by p1 and
p5 cells from the sorted CD44
high/CD24
high and CD44
high/CD24
low populations. The data shown are average number of mammospheres formed/1000
seeded cells 6SEM from triplicate values of experiments repeated twice with similar results (E) Immunoblot analysis for TG2 expression in p1 and p5
cells from the sorted CD44
high/CD24
high and CD44
high/CD24
low populations.
doi:10.1371/journal.pone.0020701.g004
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may result from dynamic equilibrium that exists between CSCs
and non-CSCs [25,26]. Moreover, this equilibrium may shift in
one or another direction in context to specific signals within the
tumor microenvironment that influence the probability of
interconversion of CSC and non-CSC compartments [27].
Moreover, our data provide additional evidence supporting that
constitutive expression of TG2 contributes to the increased
phenotypic plasticity in mammary epithelial cells.
Many primary epithelial tumor cell types rely on the EMT
program to facilitate the execution of successful invasion-
metastasis cascade [28]. Earlier we and other groups have
observed that aberrant expression of TG2 is associated with
metastatic and drug resistance phenotypes in breast cancer cells
[6–9,29,30]. In line with these observations, we recently found
that TG2 expression induces EMT in non-transformed and
malignant mammary epithelial cells and facilitates the execu-
tion of most steps in the invasion-metastasis cascade [10].
However, the last step, termed colonization, which involves the
growth of micrometastases into macroscopic metastases, has
represented a conceptual dilemma; if vast majority of cells
leaving the primary tumor and disseminating to distant sites
lack self-renewal capability, their ability to form macroscopic
metastases can be compromised because of limited proliferative
potential. Our current findings address this dilemma and
suggest that TG2-induced EMT may not only enable cancer
cell to disseminate from the primary tumors but also endow
many of the properties of stem cells such as, expression of
CD44
high/CD24
low antigenic phenotype, ability to form
mammosphere, self -renew ability and multilineage differenti-
ation. Importantly, we found that aberrant expression of TG2
enhances the self-renewal ability in both normal and malignant
mammary stem cells and shifts the dynamic equilibrium from
non-stem cells towards stem cells. In contrast, downregulation
of TG2 not only compromised the self-renewal ability of cells
but also restored the homeostasis of dynamic equilibrium
between stem and non-stem cells. The observation that self-
renewal ability of cancer cells is critical for the successful
formation of macroscopic metastasis in conjunction with the
current observation that TG2 promotes the self-renewal ability,
further supported our earlier observations that metastatic
breast tumors express high basal levels of TG2 [6].
To our knowledge, these data provide the first evidence
supporting that TG2-expression in mammary epithelial cells
bestows stem cell traits (CD44
high/CD24
low/- phenotype,
ability to form mammospeheres, self-renewal, and differenti-
ation into basal and luminal cells). Similarly, high basal
expression of TG2 in breast cancer cells (MDA-231, MCF7/
RT) though promotes certain stem cell properties (CD44
high/
CD24
low/- phenotype, ability to form mammospheres, and self-
Figure 5. TG2 expression does not affect the differentiation ability of mammary stem cells. Mammospheres formed by indicated cell type
were subsequently grown for 12 days in Matrigel containing prolactin (2 mg/ml). Differentiated structures were immunostained for basal (CD49f/
integrin a6) and luminal (Muc1) cell markers. (A) Phase-contrast images of secondary structures formed by Matrigel cultures of indicated
mammospheres in the presence of prolactin. (B). The differentiated structures from 10A-Vec and 10A-TG2-derived mammospheres show the
presence of luminal (red), basal (green), and bipotent (yellow) cells. MDA-231 mammospheres, in contrast, under these conditions failed to
differentiate into secondary structures (A) and did not show luminal marker expression but showed only low basal cell marker expression.
doi:10.1371/journal.pone.0020701.g005
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tiation. These results reveal a novel function of TG2 in cancer
cells and suggest that its aberrant expression promotes the
EMT and stem cell-like properties in mammary epithelial cells.
Furthermore, these results also support earlier observations
that TG2 expression is associated with the drug resistance and
metastasis of breast cancer [6–8], hence TG2 represents a
promising therapeutic target for the treatment of metastatic
breast disease.
Materials and Methods
Cell lines and vectors
The immortalized human mammary epithelial cell line
MCF10A and breast cancer cell lines MCF7, MCF7-RT and
MDA-231 were maintained as previously described [7,8,10]. The
open reading frame of TG2 was subcloned into a pCDH lentiviral
vector (System Biosciences, Frederick, MD) from a pcDNA3.1-
TG2 vector (kindly provided by Dr. Gail Johnson, University of
Rochester, NY). 10A-Vec and 10A-TG2 cells were established by
retroviral infection of MCF10A cells as described previously [10].
Stable clones were selected against 800 ng/ml puromycin.
Multiple stable clones were used to rule out potential clonal
effects. All experiments were performed between passages 5 and
25. MDA-231, MCF7/RT and 10A-TG2 cells were transfected
with control-shRNA or TG2-shRNA lentiviral particles according
to instructions provided by the supplier (Santa Cruz, CA).
FACS analysis
The anti-CD44 (clone G44-26) and anti-CD24 (clone ML5)
antibodies used for fluorescence-activated cell sorting (FACS)
analysis were obtained from BD Biosciences (San Jose, CA).
Briefly, for each cell line, 5610
5 cells were aliquoted into 2
tubes; tube 1 was stained with IgG isotype controls for FITC
and PE; tube 2 was stained with anti-CD44-FITC and anti-
CD24-PE. Cells were incubated with the appropriate antibodies
at room temperature in the dark for 30 minutes and then
washed with PBS. Cells were analyzed using a 4-color
FACSCalibur flow cytometer (BD Biosciences); each sample
recquired 10,000 cells for analysis. To separate CD44
high/
CD24
low ( s t e mc e l l s )f r o mC D 4 4
high/CD24
high (non stem cells)
MCF10A cells, flow cytometric cell sorting was performed on
single-cell suspensions that were stained with CD44 and CD24
antibody.
Mammosphere culture
Mammosphere were cultured as described in Dontu et al.
[14], except that the culture medium (serum-free MammoCultH
medium from Stem Cell Technology, Vancouver, Canada)
contained 0.9% methylcellulose to prevent cell aggregation.
The mammospheres were cultured for 7–10 days and mammo-
spheres with diameter .75 mmw e r ec o u n t e d .F o rs e r i a l
passages, mammospheres were collected by gentle centrifuga-
tion (800 rpm) and dissociated enzymatically (10 min in 0.05%
trypsin, 0.53 mM EDTA) and mechanically, using a fire-
polished Pasteur pipette. The dissociated cells were passed
through a 40-mm sieve and checked under a light microscope
for single-cellularity. One thousand dissociated cells were
plated in a 6-well ultra-low attachment plate and cultured for
10 days. To check the self-renewal ability of the cells,
mammospheres derived from two-dimensional culture were
serially passaged for up to four generations in the mammo-
sphere medium.
Mammosphere differentiation and immunofluorescence
The mammosphere differentiation assay was adopted from
Dontu et al. [14] and Weaver and Bissell [31]. Essentially,
mammospheres were collected by gentle centrifugation (800
rpm); washed twice with PBS to remove the methylcellulose;
resuspended in mammary epithelial cell growth medium
(Clonetics, San Diego, CA) supplemented with 4% Matrigel
(BD Biosciences), 10 ng/ml fibroblast growth factor (BD
Biosciences), 4 ng/ml heparin (Sigma, St Louis, MO), and
2 mg/ml prolactin (Invitrogen, Carlsbad, CA); plated on eight-
chambered slides pre-coated with Matrigel and allowed to grow
for an additional 10–12 days. The structures generated by
Matrigel culture were then photographed.
For immunofluorescence staining of the cell structures,
Matrigel was first dissolved by incubation with gel recovery
solution (BD Biosciences) for 2 hr at 4uC. Subsequently, the
dissolved Matrigel and remaining media were gently removed,
and the structures were fixed with 2% buffered formalin in PBS
for 20 minutes at room temperature and washed three times
with PBS containing 100 mM glycine. Cells were permeabi-
lized with 0.5% Triton X-100 and blocked with 10% goat
serum in immunofluorescence wash buffer for 1 hr at room
temperature and incubated with primary anti-CD49f/integrin
a6 (GoH3, Pharmingen, San Diego, CA) or anti-Muc1
(HMPV, Pharmingen) antibody overnight at 4uC. Subsequent-
ly, samples were washed three times with immunofluorescence
wash buffer and incubated with Alexa-conjugated secondary
antibodies (Invitrogen) for 1 hr at room temperature, and
washed three more times with wash buffer. For nuclear
staining, cells were incubated with 5 ng/ml 49-6-Diamidino-2-
phenylindole (DAPI) in PBS for 10 min, washed with PBS, and
mounted with Prolong antifade mount (Invitrogen). Slides were
viewed under a Laser-Scanning Confocal microscope (Olym-
pus, Hicksville, NY).
Western blotting
Cells were lysed in 50 mM Tris-HCl buffered saline (pH 7.5),
containing 0.5% NP-40 on ice. Fifty micrograms of total protein
from each sample was resolved on a 4%–12% bis-Tris gel with
MOPS Running Buffer (Invitrogen) and transferred to Polyviny-
lidene fluoride membranes (PVDF). The membranes were then
probed with appropriate primary and secondary antibodies.
Supporting Information
Figure S1 Number of mammospheres formed by MDA-
231 cells at different passages (M1 to M4). The data shown
are average number of mammospheres formed/1000 seeded cells
6 SEM from triplicate values from a representative experiment,
repeated twice with similar results.
(TIF)
Figure S2 FACS analysis of cell-surface markers CD44
and CD24 during passage p5 of cells sorted for CD44
high/
CD24
high and CD44
high/CD24
low subpopulations.
(TIF)
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